IASLC World Conference on Lung Cancer | Conference

Dr. Camidge on the Unmet Needs for Lung Cancer

October 25th 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with lung cancer.

Dr. Drilon on MET-Amplified Lung Cancer

October 25th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

Dr. Garassino Discusses Recent Pivotal Immunotherapy Findings in NSCLC

October 19th 2017

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses some of the recent exciting results regarding immunotherapy in non-small cell lung cancer (NSCLC).

Frontline Pembrolizumab More Than Doubles OS in PD-L1+ NSCLC

October 19th 2017

Two-year results showed that frontline pembrolizumab (Keytruda) more than doubled median overall survival compared with standard chemotherapy in patients with high PD-L1 expressing non–small cell lung cancer

Ado-Trastuzumab Emtansine Shows Activity in HER2-Mutated, Amplified Lung Cancer

October 19th 2017

Ado-trastuzumab emtansine (Kadcyla) is active and well tolerated in patients with advanced HER2-mutant or amplified lung cancers as identified by next generation sequencing.

Dr. Doebele on Significant Findings of Entrectinib in Patients With ROS1+ NSCLC

October 19th 2017

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non

Entrectinib Impresses for ROS1-Positive NSCLC

October 18th 2017

Treatment with entrectinib induced an objective response rate of 68.8% by blinded independent central review, which included 2 complete responses (6.3%), for patients with ROS1 fusion-positive advanced non–small cell lung cancer.

Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC

October 18th 2017

The potent small molecule TKI ensartinib has shown promise and meaningful intercranial activity in ALK-positive, TKI-naïve patients with non–small cell lung cancer.

Frontline Lorlatinib Induces 90% Response in ALK+ NSCLC

October 18th 2017

Lorlatinib induced an objective response rate of 90% in treatment-naïve patients with ALK-positive non–small cell lung cancer.

Durvalumab Delivers on QoL Post Chemo RT in PACIFIC Trial

October 18th 2017

Patient reported outcomes from the PACIFIC trial of durvalumab versus placebo after chemoradiation in locally advanced unresectable NSCLC show that durvalumab had no serious impact on quality of life.

ctDNA EGFR Testing Identifies Proper Patients for Frontline Osimertinib

October 18th 2017

There was a high concordance between central tissue and plasma circulating tumor DNA testing for EGFR mutations in patients enrolled in the phase III FLAURA study of frontline osimertinib (Tagrisso) in NSCLC.

Dr. Oxnard on Detecting Resistance Mechanisms After Treatment With Osimertinib

October 17th 2017

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses resistance mechanisms that occur in patients with EGFR-positive T790M non

MET/EGFR Combo Effective for Advanced NSCLC

October 17th 2017

The combination of osimertinib and the MET inhibitor savolitinib showed signs of efficacy for pretreated patients with MET-positive, EGFR-mutant non–small cell lung cancer.

Dr. Drilon on Entrectinib in Patients With ROS1-Positive NSCLC

October 17th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a study exploring entrectinib in patients with ROS1-positive, advanced or metastatic non-small cell lung cancer (NSCLC) during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

Dacomitinib Stands Out in EGFR-Mutated Subtype Response

October 17th 2017

Second-generation EGFR inhibitor dacomitinib showed clear superiority over first-generation TKI gefitinib (Iressa) in a comparison of performance in EGFR mutation subtypes exon 19 deletion and L858R in advanced NSCLC.

Ramucirumab Associated With OS Benefit in Aggressive NSCLC

October 17th 2017

Ramucirumab (Cyramza) plus docetaxel demonstrated an overall survival benefit versus placebo plus docetaxel in patients with advanced NSCLC whose disease rapidly progressed on first-line therapy,

Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC

October 16th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer (NSCLC).

Dr. Camidge on the ALTA Study of Brigatinib in NSCLC

October 16th 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the ALTA trial, which is exploring brigatinib (Alunbrig) in patients with ALK-positive non-small cell lung cancer.

Lower Dose Ceritinib With Food as Effective But Better Tolerated for ALK+ NSCLC

October 16th 2017

A lower dose of ceritinib taken with a low-fat meal showed similar efficacy with fewer dose reductions and less severe gastrointestinal adverse events versus a 750-mg dose taken without food for patients with untreated ALK-positive metastatic non–small cell lung cancer.

Nivolumab/Ipilimumab Combo Active in SCLC With High Tumor Burden

October 16th 2017

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced an objective response rate of 46% in patients with recurrent small cell lung cancer with high tumor mutation burden, according to an exploratory analysis from the phase I/II CheckMate-032 study.